A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

Summary

Neuroblastoma is one of the most common solid childhood tumours, and a major cause of cancer-related death in children. More than 1200 children/young adults a year are diagnosed in USA and Europe. Around 600 of these cases are considered high-risk, which means the cancer is more difficult to treat successfully. Despite improvements in survival over recent decades, a significant proportion of patients with high-risk neuroblastoma have disease that does not respond to standard treatments (refractory neuroblastoma) or comes back after completion of standard frontline treatment (relapsed neuroblastoma). Therefore, there is a need to develop new treatment strategies and test new drugs to improve outcomes for children with neuroblastoma.

Aims Of The BEACON2 Trial

* To improve survival for patients with relapsed neuroblastoma by developing new treatment combinations
* To evaluate new treatment combinations in relapsed neuroblastoma, within a phase I/II trial that can impact clinical practice, while also allowing dose confirmation for new promising combinations
* To evaluate the safety, activity, efficacy and impact on quality of life of these new treatment combinations in relapsed neuroblastoma patients
* To improve our understanding of relapsed neuroblastoma biology and advance the development of targeted therapies using biomarkers, by conducting a comprehensive biomarker sample collection.

Trial Design BEACON2 is a randomised phase I/phase II, open label, international trial. The trial will have two tiers: Tier 1 will be the main randomisation for two treatment arms initially. Participants will be randomised at trial entry to receive one of the available regimens, treatment A or treatment B. Tier 2 will include smaller dose expansion/confirmation cohorts for more novel experimental treatment combinations (Arm C and future arms), with the potential for them to be moved to Tier 1.

Current Tier 1 (Randomisation Tier) Treatment Arms in the BEACON2 Trial:

Arm A: dbIT Treatment with dinutuximab beta, irinotecan, and temozolomide, 3 weekly x12 cycles Arm B: BIT Treatment with bevacizumab, irinotecan, and temozolomide, 3 weekly x12 cycles

Current Tier 2 (Registration Only Tier) Treatment Arms in the BEACON2 Trial:

Arm C: dbBIT Treatment with dinutuximab beta, bevacizumab, irinotecan, and temozolomide, 3 weekly x12 cycles

Patient Population and Sample Size Patients aged ≥1 years of age with relapsed neuroblastoma. For each arm in Tier 1, up to 75 patients will be recruited to complete phase 2 investigations. For each arm in Tier 2, 10 patients will be recruited to complete phase I investigations. Approximately 160 participants are initially planned, 75 in each arm of Tier 1 and 10 participants for one dose-confirmation cohort in Tier 2.

The study is expected to recruit patients for 3 years, and then finish patient follow-up after an additional 5 years.

Translational Sub-study / Biological Studies

It is standard of care for patients diagnosed with relapsed neuroblastoma to:

* Have had a tumour sample collected at point of initial diagnosis (either during biopsy or surgery)
* Have bloods collected before they start and during treatment for their relapsed neuroblastoma
* Have a bone aspirate/trephine procedure in order to help confirm relapse. These samples provide very important opportunities for further research, and the study investigators would like to make full use of these opportunities by collecting the analysis already performed on these samples and collect some additional samples (at the same time as the standard ones) to learn and understand more about neuroblastoma and its treatment. Samples will undergo research analysis at the national SIOPEN reference laboratories.

Conditions

• Relapsed Neuroblastoma

Interventions

DRUG

Bevacizumab

Bevacizumab

DRUG

Dinutuximab beta

Dinutuximab beta

DRUG

Irinotecan (drug)

Irinotecan

DRUG

Topotecan

Topotecan

DRUG

Temozolomide (TMZ)

Temozolomide capsule

DRUG

Temozolomide (TMZ)

Temozolomide liquid suspension

Sponsors & Collaborators

• University of Birmingham

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

1 Year

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-11-11

Primary Completion

2030-12-31

Completion

2030-12-31

Countries

• Australia
• Austria
• Belgium
• New Zealand
• United Kingdom

Study Locations